In a small, non-randomized clinical trial, the diabetic medication and DPP4 inhibitor, sitagliptin, was administered from day -1 to day +14 of alloHCT, resulting in a low incidence (5%) of grades II-IV GVHD followed to day +100 (34). The gene discussed is DPP4; the disease is graft versus host disease.